Subscribe
lightspring-money-competition
Lightspring / Shutterstock.com
29 August 2023FeaturesBig PharmaAndrei Iancu and David Kappos

Everybody loses in the end: Billion-dollar government prizes won't improve on market incentives

In his latest attempt to replace America's free market with government regulators to set prices for medicines, Senator Bernie Sanders wants to reward drug developers with cash prizes determined in Washington. In his vision, these would replace the current US patent system.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Repurposed drugs: protections and incentives
13 April 2021   Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired.
Americas
Zetia buyers secure backing for ‘market narrowing’ in MSD antitrust case
4 November 2021   Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Generics
Repurposed drugs: protections and incentives
13 April 2021   Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired.
Americas
Zetia buyers secure backing for ‘market narrowing’ in MSD antitrust case
4 November 2021   Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark.

More on this story

Generics
Repurposed drugs: protections and incentives
13 April 2021   Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired.
Americas
Zetia buyers secure backing for ‘market narrowing’ in MSD antitrust case
4 November 2021   Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
Sandoz wins $137.2m payout for lost profits in generic launch
Dexcom suffers second patent revocation at hands of UPC
Sanofi signs global rights deal to develop rare cancer therapy
WBD to merge with firm to create ‘powerhouse’ practice
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
AstraZeneca unit draws line under Samsung dispute